JP2023058678A5 - - Google Patents

Download PDF

Info

Publication number
JP2023058678A5
JP2023058678A5 JP2023022208A JP2023022208A JP2023058678A5 JP 2023058678 A5 JP2023058678 A5 JP 2023058678A5 JP 2023022208 A JP2023022208 A JP 2023022208A JP 2023022208 A JP2023022208 A JP 2023022208A JP 2023058678 A5 JP2023058678 A5 JP 2023058678A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
less
active agent
suspension
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023022208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023058678A (ja
Filing date
Publication date
Priority claimed from JP2020214665A external-priority patent/JP7232235B2/ja
Application filed filed Critical
Publication of JP2023058678A publication Critical patent/JP2023058678A/ja
Publication of JP2023058678A5 publication Critical patent/JP2023058678A5/ja
Priority to JP2024107963A priority Critical patent/JP2024129122A/ja
Ceased legal-status Critical Current

Links

JP2023022208A 2015-01-20 2023-02-16 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 Ceased JP2023058678A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024107963A JP2024129122A (ja) 2015-01-20 2024-07-04 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562105565P 2015-01-20 2015-01-20
US62/105,565 2015-01-20
US201562272922P 2015-12-30 2015-12-30
US62/272,922 2015-12-30
JP2020214665A JP7232235B2 (ja) 2015-01-20 2020-12-24 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020214665A Division JP7232235B2 (ja) 2015-01-20 2020-12-24 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024107963A Division JP2024129122A (ja) 2015-01-20 2024-07-04 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法

Publications (2)

Publication Number Publication Date
JP2023058678A JP2023058678A (ja) 2023-04-25
JP2023058678A5 true JP2023058678A5 (https=) 2023-11-07

Family

ID=55410198

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017556790A Pending JP2018503686A (ja) 2015-01-20 2016-01-20 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法
JP2020214665A Active JP7232235B2 (ja) 2015-01-20 2020-12-24 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法
JP2023022208A Ceased JP2023058678A (ja) 2015-01-20 2023-02-16 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法
JP2024107963A Pending JP2024129122A (ja) 2015-01-20 2024-07-04 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017556790A Pending JP2018503686A (ja) 2015-01-20 2016-01-20 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法
JP2020214665A Active JP7232235B2 (ja) 2015-01-20 2020-12-24 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024107963A Pending JP2024129122A (ja) 2015-01-20 2024-07-04 レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法

Country Status (16)

Country Link
US (3) US10117843B2 (https=)
EP (2) EP3247330A1 (https=)
JP (4) JP2018503686A (https=)
KR (1) KR20170103967A (https=)
CN (2) CN107427463A (https=)
AU (1) AU2016209420B2 (https=)
BR (1) BR112017015613B1 (https=)
CA (1) CA2974203A1 (https=)
IL (1) IL253487A0 (https=)
MA (1) MA41377A (https=)
MX (1) MX384262B (https=)
PH (1) PH12017501304A1 (https=)
RU (1) RU2017129375A (https=)
SG (1) SG11201705964YA (https=)
TW (1) TW201639556A (https=)
WO (1) WO2016118556A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
JP2019523249A (ja) * 2016-07-20 2019-08-22 アッヴィ・インコーポレイテッド レボドパ及びカルビドパ腸管ゲル、並びに使用方法
BR112021009353A2 (pt) 2018-11-15 2021-11-23 Abbvie Inc Formulações farmacêuticas para administração subcutânea
CN119510592A (zh) * 2023-08-22 2025-02-25 上海汉都医药科技有限公司 一种含有卡比多巴的药物中肼含量的检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
ES2070994T3 (es) 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
WO2007138086A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24 hour intestinal administration of levodopa/carbidopa
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
PL2432454T3 (pl) 2009-05-19 2017-10-31 Neuroderm Ltd Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
PT2640358T (pt) * 2010-11-15 2018-02-23 Neuroderm Ltd Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
WO2012079072A2 (en) 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
WO2013033453A2 (en) * 2011-08-31 2013-03-07 Abbott Laboratories Sealing arrangement for syringe
AU2014229127B2 (en) 2013-03-13 2018-04-05 Neuroderm Ltd Method for treatment of parkinson's disease
CN113384373B (zh) 2013-11-05 2022-10-21 辛纳吉勒公司 经由口腔进行连续药物递送的装置和方法
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Similar Documents

Publication Publication Date Title
JP2023058678A5 (https=)
JP2022105175A5 (https=)
JP2024129122A5 (https=)
CN109350611B (zh) 包覆魔芋葡甘露聚糖的nmn纳米微球及其制备工艺与应用
JP2019501215A (ja) 局所皮膜形成スプレー
RU2017129375A (ru) Интестинальный гель на основе леводопы и карбидопы и способы его применения
GB0814302D0 (en) Compounds and methods
JP2022166217A5 (https=)
CN103394091A (zh) 消炎镇痛外用剂
JP2023509463A5 (https=)
JP2022166217A (ja) レボドパ及びカルビドパ腸管ゲル、並びに使用方法
MX2025007901A (es) Formulación inyectable que comprende un agente biofarmacéutico y un copolímero basado en poliacrilamida
CN105412040B (zh) 一种硝苯地平控释片及其制备方法
JP2018500365A5 (https=)
CN115813920A (zh) 1,2,4三唑并4,3-b哒嗪衍生物在制备治疗慢性肾病的药物中的应用
CN112516159B (zh) 一种含有硝酸盐的组合物、胃漂浮剂及制备方法和应用
WO2019170912A1 (en) Bioresorbable controlled-release compositions with sting modulating molecules
RU2010129409A (ru) Способ лечения псороптоза кроликов и отодектоза плотоядных животных
CN101181230A (zh) 一种治疗实体肿瘤的雌二醇氮芥缓释植入剂
JP2001522885A (ja) 血中ヒスタミンレベルを上昇させるためのヒスタミンの使用
CN116763718A (zh) 一种紫杉醇纳米晶温敏凝胶及其制备方法和其应用
WO2000047232A1 (fr) Implant a liberation prolongee, son procede de preparation et traitement du cancer
CN101185629A (zh) 一种治疗实体肿瘤的地西他滨缓释剂
KR20160009677A (ko) 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합
CN104940145B (zh) 一种提高载药微球控释能力的方法